During the past decade, AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM" #1 collaborator was "Institut National de la Santé Et de la Recherche Médicale, France" with 3 trials as a collaborator, "Vanderbilt University Medical Center" with 3 trials as a collaborator, "Institute of Cardiometabolism and Nutrition, France" with 1 trials as a collaborator and "Vanderbilt University" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM" are "Cardiac Complication" (3 trials), "Myocarditis" (3 trials), "Adverse Drug Event" (2 trials), "Arthritis" (2 trials) and "Cancer" (2 trials). Many other conditions were trialed in "AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM" in a lesser frequency.

Most popular intervention types in "AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM" are "Drug" (14 trials), "Other" (2 trials), "Biological" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "ICI" (2 trials), "Anti-Cancer Agents" (1 trials), "Antineoplastic and Immunomodulating Agents" (1 trials), "Cardiac complication induced by VEGF/VEGFR inhibitor" (1 trials) and "Clinical exam and DFU medical cares" (1 trials). Other intervention names were less common.

The vast majority of trials in "AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM" are 17 trials for "All" genders.

Currently, there are NaN active trials in "AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".